Oncternal Therapeutics, Inc. announced that Damien Bresson as Senior Director, Preclinical and Translation Science.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.179 USD | -5.28% | -9.12% | -23.73% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.73% | 25.56M | |
+17.96% | 47.02B | |
+48.77% | 41.86B | |
+1.17% | 41.76B | |
-4.27% | 28.8B | |
+11.42% | 26.05B | |
-21.39% | 19.15B | |
+4.86% | 12.55B | |
+27.29% | 12.34B | |
-3.50% | 11.82B |
- Stock Market
- Equities
- ONCT Stock
- News Oncternal Therapeutics, Inc.
- Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science